Research & Development
Aditxt, SphereDX Launch AditxtScore for COVID-19 in Kentucky, Ohio and Indiana
10 September 2021 - - US-based biotech innovation company Aditxt, Inc. (NASDAQ: ADTX) has forged a partnership with US-based clinical diagnostic lab SphereDX to offer its AditxtScore for COVID-19, the company said.

The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens.

This makes it possible to assess the strength of an individual's immune response to COVID-19.

Under the agreement, SphereDX will make the AditxtScore for COVID-19 available throughout its laboratory locations serving Kentucky, Ohio and Indiana.

The initiative is part of Aditxt's ongoing effort to expand its immune monitoring network nationwide.

SphereDX conducted a pilot program deploying the AditxtScore for COVID-19 in a group of area assisted living facilities.

Testing a total of 99 fully vaccinated residents ages 63 to 99, the results showed that 33.3% of the residents tested had a suboptimal immune response.

Of that group, 8.1% showed no discernable immune response to COVID-19.

The CDC has recommended that people with moderately to severely compromised immune systems receive an additional dose of the mRNA COVID-19 vaccine.

AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual's immune response to multiple antigens associated with COVID-19.

This multiplex approach to capturing the full spectrum of biomarkers associated with COVID-19 delivers a highly detailed snapshot of an individual's immune response in a single test cycle.

It also includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles.

The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual's immune response to COVID-19.

AditxtScore for COVID-19 is offered through authorized channel partners.

This test is not for self-diagnosis and is not cleared or approved by the FDA.

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.

Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.


Related Headlines